BIRC5 and ovarian carcinoma: A recent study has shown that PI3K/AKT/mTOR signaling is involved in EOC development and resistance to cisplatin, since downregulation of AKT with triciribine or shRNA transfection of ovarian cancer cells decreased their resistance to cisplatin via mTOR/survivin signaling [92].